E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor

被引:66
|
作者
DiFeo, A.
Narla, G.
Camacho-Vanegas, O.
Nishio, H.
Rose, S. L.
Buller, R. E.
Friedman, S. L.
Walsh, M. J.
Martignetti, J. A.
机构
[1] Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA
[3] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA
[4] Univ Iowa Hosp & Clin, Div Gynecol Oncol, Iowa City, IA 52242 USA
[5] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA
关键词
KLF6; KLF6-SV1; E-cadherin; alternative splicing; ovarian cancer;
D O I
10.1038/sj.onc.1209611
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tumor suppressor KLF6 is a member of the Kruppel-like family of transcription factors, which has been implicated in the pathogenesis of several human carcinomas. Uncovering the transcriptional targets relevant for its tumorigenic properties, including cellular proliferation and invasion, will be essential to understanding possible mechanisms by which KLF6 and its antagonistic splice form, KLF6-SV1, regulate this development. To begin de. ning possible metastatic-related pathways, we analysed the effect of KLF6 dysregulation on a recognized suppressor of cellular invasion, E-cadherin. Targeted KLF6 reduction in an ovarian cancer cell line, SKOV-3, resulted in a 50% reduction of E-cadherin expression (P < 0.01) and conversely, KLF6-SV1 silencing upregulated E-cadherin approximately fivefold (P < 0.0001). These changes resulted from KLF6 directly transactivating the E-cadherin promoter as demonstrated by luciferase promoter assay and chromatin immunoprecipitation (ChIP). KLF6-mediated changes in E-cadherin levels were accompanied by downstream changes in both the subcellular localization of beta-catenin and c-myc expression levels. Moreover, and consistent with these experimental findings, patient-derived epithelial ovarian tumors with low KLF6 and high KLF6-SV1 expression ratios had significantly decreased E-cadherin expression (P < 0.0001). These combined findings highlight the E-cadherin pathway as a novel and functionally important mediator by which changes in KLF6 and KLF6-SV1 can directly alter ovarian tumor invasion and metastasis.
引用
收藏
页码:6026 / 6031
页数:6
相关论文
共 50 条
  • [31] E-CADHERIN AS AN INVASION-SUPPRESSOR PROTEIN IN EPITHELIAL TUMOR-CELLS
    VLEMINCKX, K
    VAKAET, L
    MAREEL, M
    FIERS, W
    VANROY, F
    JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, 1991, 12 (05) : 493 - 493
  • [32] Novel epigenetic mechanism for transcriptional silencing of E-cadherin in colorectal cancers
    Liu, Y.
    Hong, Y.
    Zhao, Y.
    Seow Choen, F.
    Eu, K.
    ANNALS OF ONCOLOGY, 2006, 17 : 42 - 42
  • [33] Tumor-associated E-cadherin mutations do not induce Wnt target gene expression, but affect E-cadherin repressors
    Laux, H
    Tomer, R
    Mader, MT
    Smida, J
    Budczies, J
    Kappler, R
    Hahn, H
    Blöchinger, M
    Schnitzbauer, U
    Eckardt-Schupp, F
    Höfler, H
    Becker, KF
    LABORATORY INVESTIGATION, 2004, 84 (10) : 1372 - 1386
  • [34] Mutational analysis of KLF6 gene in cancer, and mutated KLF6 gene affects on the cell proliferation in brain tumor
    Komatsu, Naoki
    Yin, Dong
    Chumakov, Alexy
    Marschesky, Alberto
    Robert, McKenna
    Keuchi, Seisho Ta
    Miller, Carl W.
    Koeffler, Phillip H.
    CANCER RESEARCH, 2006, 66 (08)
  • [35] Transcriptional Suppression of E-Cadherin by HPV-16 E6 and E7 Oncogenes is Independent of Hypermethylation of E-Cadherin Promoter
    Faghihloo, Ebrahim
    Sadeghizadeh, Majid
    Shahmahmoodi, Shohreh
    Mokhtari-Azad, Talat
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2017, 19 (02)
  • [36] Transcriptional Repression of E-Cadherin by Human Papillomavirus Type 16 E6
    D'Costa, Zarina J.
    Jolly, Carol
    Androphy, Elliot J.
    Mercer, Andrew
    Matthews, Charles M.
    Hibma, Merilyn H.
    PLOS ONE, 2012, 7 (11):
  • [37] SYNOVIOLIN, A TRANSCRIPTIONAL TARGET OF KLF6, REGULATES LIVER FIBROSIS THROUGH ITS ENZYMATIC ACTIVITY AS AN E3 UBIQUITIN LIGASE
    Hasegawa, Daisuke
    Fujii, Ryoji
    Yagishita, Naoko
    Matsumoto, Nobuyuki
    Aratani, Satoko
    Izumi, Toshihiko
    Azakami, Kazuko
    Nakazawa, Minako
    Fujita, Hidetoshi
    Sato, Tomoo
    Araya, Natsumi
    Senoo, Haruki
    Friedman, Scott L.
    Nishioka, Kusuki
    Yamano, Yoshihisa
    Itoh, Fumio
    Nakajima, Toshihiro
    HEPATOLOGY, 2009, 50 (04) : 365A - 365A
  • [38] The tumor suppressor KLF6, lost in a majority of ovarian cancer cases, represses VEGF expression levels
    Bradley, W.
    Dottino, P.
    Rahaman, J.
    DiFeo, A.
    Martignetti, J.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S57 - S57
  • [39] TUMOR SUPPRESSOR ACTIVITY OF KLF6 TRANSCRIPTION FACTOR IN ONCOGENESIS TRIGGERED BY ACTIVATED H-RAS
    Trucco, L. D.
    Nicola, J. P.
    Soria, G.
    Bocco, J. L.
    BIOCELL, 2014, 38 : 83 - 84
  • [40] Differential expression of the klf6 tumor suppressor gene upon cell damaging treatments in cancer cells
    Gehrau, Ricardo C.
    D'Astolfo, Diego S.
    Andreoli, Veronica
    Bocco, Jose L.
    Koritschoner, Nicolas P.
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2011, 707 (1-2) : 15 - 23